Loading...

Bio-Rad Laboratories, Inc. Peer Comparison

Metric Value Ranking
Market Cap $7.9 Billion 9/17 DXCM
$34.8B
STE
$21.6B
ZBH
$20.0B
PODD
$19.7B
SWAV
$12.6B
GMED
$11.4B
PEN
$10.3B
GKOS
$8.4B
BIO
$7.9B
BRKR
$7.6B
INSP
$5.5B
ITGR
$4.7B
NARI
$4.7B
NVCR
$2.4B
TNDM
$2.2B
CNMD
$2.0B
ANIK
$261.6M
Gross Margin 55% 11/17 PODD
100%
SWAV
87%
NARI
87%
INSP
85%
GKOS
77%
NVCR
77%
PEN
67%
DXCM
60%
GMED
57%
CNMD
57%
BIO
55%
BRKR
47%
STE
45%
TNDM
34%
ITGR
16%
ANIK
4%
ZBH
0%
Profit Margin 100% 1/17 BIO
100%
SWAV
25%
PODD
21%
CNMD
15%
INSP
15%
DXCM
14%
STE
13%
PEN
10%
GMED
8%
BRKR
5%
ITGR
5%
ZBH
0%
TNDM
-6%
NARI
-12%
NVCR
-20%
GKOS
-22%
ANIK
-77%
EBITDA margin 214% 1/17 BIO
214%
PODD
24%
INSP
24%
CNMD
21%
SWAV
19%
STE
18%
DXCM
15%
PEN
15%
GMED
8%
ITGR
8%
NARI
-5%
TNDM
-7%
BRKR
-9%
NVCR
-21%
GKOS
-26%
ANIK
-66%
ZBH
-100%
Quarterly Revenue $649.7 Million 5/17 STE
$1.4B
DXCM
$994.2M
BRKR
$864.4M
ITGR
$746.3M
BIO
$649.7M
GMED
$625.7M
PODD
$372.6M
TNDM
$363.3M
CNMD
$316.7M
PEN
$301.0M
INSP
$239.7M
SWAV
$218.8M
NVCR
$155.1M
NARI
$153.4M
GKOS
$96.7M
ANIK
$38.8M
ZBH
$0
Quarterly Earnings $653.2 Million 1/17 BIO
$653.2M
STE
$173.5M
DXCM
$134.6M
PODD
$77.5M
SWAV
$55.3M
GMED
$51.8M
CNMD
$49.0M
BRKR
$40.9M
ITGR
$35.4M
INSP
$35.2M
PEN
$29.5M
ZBH
-$0
NARI
-$18.4M
GKOS
-$21.4M
TNDM
-$23.3M
ANIK
-$29.9M
NVCR
-$30.6M
Quarterly Free Cash Flow $246.7 Million 1/17 BIO
$246.7M
STE
$243.6M
GMED
$161.7M
ITGR
$131.8M
DXCM
$88.3M
PODD
$76.1M
INSP
$62.2M
PEN
$51.0M
CNMD
$47.8M
SWAV
$27.5M
TNDM
$21.5M
BRKR
$5.8M
ANIK
$3.8M
NVCR
-$307,000
NARI
-$995,000
GKOS
-$11.0M
ZBH
-$0
Trailing 4 Quarters Revenue $2.7 Trillion 1/17 BIO
$2.7T
ZBH
$5.7B
STE
$5.4B
DXCM
$4.0B
BRKR
$3.2B
GMED
$2.5B
ITGR
$2.0B
PODD
$1.8B
CNMD
$1.3B
PEN
$1.2B
TNDM
$973.7M
INSP
$802.8M
SWAV
$788.0M
NVCR
$577.7M
NARI
$574.5M
GKOS
$360.3M
ANIK
$164.2M
Trailing 4 Quarters Earnings -$637.5 Billion 17/17 STE
$1.4B
DXCM
$994.2M
BRKR
$864.4M
ITGR
$746.3M
BIO
$649.7M
GMED
$625.7M
PODD
$372.6M
TNDM
$363.3M
CNMD
$316.7M
PEN
$301.0M
INSP
$239.7M
SWAV
$218.8M
NVCR
$155.1M
NARI
$153.4M
GKOS
$96.7M
ANIK
$38.8M
ZBH
-$0
Quarterly Earnings Growth 515% 2/17 GMED
5094%
BIO
515%
PEN
220%
CNMD
209%
INSP
139%
PODD
49%
SWAV
41%
NVCR
38%
GKOS
30%
ITGR
30%
TNDM
29%
STE
23%
DXCM
12%
ZBH
0%
BRKR
-54%
ANIK
-355%
NARI
-681%
Annual Earnings Growth -18757% 17/17 INSP
593%
PODD
215%
CNMD
131%
DXCM
45%
ZBH
36%
NVCR
32%
BRKR
18%
ITGR
15%
TNDM
10%
STE
-4%
GKOS
-16%
GMED
-47%
PEN
-48%
SWAV
-65%
ANIK
-559%
NARI
-934%
BIO
-18757%
Quarterly Revenue Growth 3% 12/17 TNDM
96%
GMED
63%
SWAV
36%
INSP
25%
GKOS
24%
NVCR
22%
NARI
21%
BRKR
16%
PEN
11%
ITGR
6%
CNMD
4%
BIO
3%
DXCM
2%
STE
-2%
ANIK
-7%
PODD
-14%
ZBH
-100%
Annual Revenue Growth 99740% 1/17 BIO
99740%
GMED
97%
SWAV
33%
TNDM
26%
INSP
23%
NARI
19%
BRKR
16%
NVCR
14%
GKOS
13%
PODD
12%
DXCM
10%
PEN
10%
ITGR
6%
ZBH
4%
CNMD
2%
STE
0%
ANIK
-6%
Cash On Hand $410.4 Million 5/17 PODD
$902.6M
GMED
$622.8M
DXCM
$621.2M
ZBH
$525.5M
BIO
$410.4M
SWAV
$281.7M
PEN
$280.5M
STE
$155.2M
INSP
$150.2M
BRKR
$148.1M
GKOS
$100.1M
ANIK
$62.4M
TNDM
$49.0M
NARI
$41.1M
CNMD
$38.5M
ITGR
$35.6M
NVCR
-$0
Short Term Debt $1.3 Million 14/17 ZBH
$863.0M
STE
$125.0M
NVCR
$86.4M
PODD
$42.0M
BRKR
$32.8M
DXCM
$22.3M
TNDM
$18.0M
PEN
$14.5M
ITGR
$13.9M
GMED
$11.0M
SWAV
$3.7M
ANIK
$2.3M
NARI
$1.6M
BIO
$1.3M
CNMD
$717,000
GKOS
-$0
INSP
-$0
Long Term Debt $1.2 Billion 5/17 ZBH
$5.3B
DXCM
$2.5B
BRKR
$2.3B
PODD
$1.4B
BIO
$1.2B
ITGR
$1.2B
CNMD
$940.1M
SWAV
$773.1M
GMED
$523.5M
TNDM
$457.9M
PEN
$212.2M
GKOS
$157.1M
STE
$123.7M
NARI
$31.1M
INSP
$30.0M
ANIK
$25.2M
NVCR
$0
PE -1.00 12/17 PEN
298.47
GMED
124.88
INSP
102.92
SWAV
76.87
DXCM
51.10
PODD
46.76
STE
46.09
ITGR
41.65
ZBH
30.12
BRKR
24.88
CNMD
14.81
BIO
-1.00
GKOS
-1.00
TNDM
-1.00
NVCR
-1.00
ANIK
-1.00
NARI
-1.00
PS 0.00 17/17 GKOS
23.44
SWAV
15.95
PODD
10.86
PEN
8.86
DXCM
8.80
NARI
8.15
INSP
6.86
GMED
4.61
NVCR
4.21
STE
3.99
ZBH
3.54
ITGR
2.35
BRKR
2.34
TNDM
2.26
ANIK
1.59
CNMD
1.51
BIO
0.00
PB 1.06 16/17 PODD
17.60
DXCM
17.58
SWAV
16.72
GKOS
12.64
NARI
10.77
PEN
9.34
TNDM
9.25
INSP
7.98
BRKR
4.12
STE
3.35
ITGR
2.92
GMED
2.81
CNMD
2.09
ANIK
1.45
ZBH
1.39
BIO
1.06
NVCR
0.00
PC 19.34 14/17 STE
138.87
ITGR
132.95
NARI
113.78
GKOS
84.35
DXCM
56.00
BRKR
51.22
CNMD
50.71
TNDM
44.83
SWAV
44.62
ZBH
38.08
PEN
36.76
INSP
36.68
PODD
21.80
BIO
19.34
GMED
18.35
ANIK
4.19
NVCR
-1.00
Liabilities to Equity 0.42 12/17 TNDM
3.03
NVCR
2.39
BRKR
2.34
DXCM
2.21
PODD
1.71
CNMD
1.48
SWAV
1.19
ITGR
0.95
NARI
0.60
STE
0.56
ZBH
0.48
BIO
0.42
GKOS
0.39
PEN
0.34
ANIK
0.29
GMED
0.25
INSP
0.17
ROA -60.12 17/17 PODD
14%
DXCM
11%
SWAV
10%
INSP
7%
CNMD
6%
BRKR
5%
STE
5%
ITGR
4%
ZBH
3%
GMED
2%
PEN
2%
NARI
-11%
TNDM
-13%
GKOS
-16%
ANIK
-42%
NVCR
-100%
BIO
-6012%
ROE -85.13 17/17 PODD
38%
DXCM
34%
SWAV
22%
BRKR
17%
CNMD
14%
INSP
8%
STE
7%
ITGR
7%
ZBH
5%
PEN
3%
GMED
2%
NARI
-18%
GKOS
-22%
NVCR
-42%
TNDM
-53%
ANIK
-54%
BIO
-8513%
Current Ratio 3.40 6/17 INSP
6.81
GMED
5.00
ANIK
4.49
PEN
3.95
GKOS
3.59
BIO
3.40
ZBH
3.08
STE
2.80
NARI
2.66
ITGR
2.05
SWAV
1.84
CNMD
1.67
PODD
1.59
DXCM
1.45
BRKR
1.43
TNDM
1.33
NVCR
0.00
Quick Ratio 0.52 9/17 PEN
298.47
GMED
124.88
INSP
102.92
SWAV
76.87
DXCM
51.10
PODD
46.76
STE
46.09
ITGR
41.65
ZBH
30.12
BRKR
24.88
CNMD
14.81
BIO
-1.00
GKOS
-1.00
TNDM
-1.00
NVCR
-1.00
ANIK
-1.00
NARI
-1.00
Long Term Debt to Equity 0.16 11/17 TNDM}
1.93
DXCM}
1.27
BRKR}
1.24
PODD}
1.21
SWAV}
1.03
CNMD}
1.01
ITGR}
0.71
ZBH}
0.37
GKOS}
0.24
PEN}
0.19
BIO}
0.16
ANIK}
0.14
GMED}
0.13
NARI}
0.07
INSP}
0.04
STE}
0.02
NVCR}
0.00
Debt to Equity 0.16 12/17 TNDM
2.00
DXCM
1.28
BRKR
1.26
PODD
1.25
SWAV
1.03
CNMD
1.01
ITGR
0.72
ZBH
0.43
GKOS
0.24
NVCR
0.24
PEN
0.21
BIO
0.16
GMED
0.13
NARI
0.08
INSP
0.04
STE
0.02
ANIK
0.01
Burn Rate -0.68 8/17 GKOS
3.62
BRKR
2.56
ITGR
2.48
NARI
2.06
ANIK
1.98
TNDM
1.06
NVCR
0.00
BIO
-0.68
ZBH
-1.00
STE
-1.13
CNMD
-3.43
INSP
-4.41
SWAV
-11.98
PEN
-16.10
DXCM
-21.72
GMED
-22.13
PODD
-70.80
Cash to Cap 0.05 2/17 ANIK
0.24
BIO
0.05
PODD
0.05
GMED
0.05
ZBH
0.03
PEN
0.03
INSP
0.03
TNDM
0.02
DXCM
0.02
BRKR
0.02
CNMD
0.02
SWAV
0.02
GKOS
0.01
STE
0.01
ITGR
0.01
NARI
0.01
NVCR
0.00
CCR 0.38 11/17 ITGR
3.72
GMED
3.12
INSP
1.76
PEN
1.73
STE
1.40
PODD
0.98
CNMD
0.98
DXCM
0.66
GKOS
0.52
SWAV
0.50
BIO
0.38
BRKR
0.14
NARI
0.05
NVCR
0.01
ANIK
-0.13
TNDM
-0.93
ZBH
EV to EBITDA 6.28 10/17 SWAV}
308.03
DXCM}
241.46
GMED}
235.78
PEN}
231.75
PODD}
229.01
ITGR}
101.10
INSP}
94.92
STE}
87.73
CNMD}
43.42
BIO}
6.28
ZBH}
-1.00
ANIK}
-7.88
NVCR}
-78.48
TNDM}
-100.61
BRKR}
-126.60
GKOS}
-344.85
NARI}
-648.07
EV to Revenue 0.00 16/17 GKOS
23.60
SWAV
16.58
PODD
11.13
DXCM
9.28
PEN
8.81
NARI
8.13
INSP
6.71
GMED
4.58
NVCR
4.36
STE
3.99
BRKR
3.00
ITGR
2.92
TNDM
2.70
CNMD
2.21
ANIK
1.23
BIO
0.00
ZBH
-1.00